Market Place
Sourcing Support
Astellas Ends $1.6B Biobucks TCE Pact With Cytomx After 6 Years
17 Mar 2026 //
FIERCE BIOTECH
Cytomx Therapeutics Reveals 2025 Financials And Business Update
16 Mar 2026 //
GLOBENEWSWIRE
Varsetatug Masetecan Shows Promise in Late-Line Colorectal Cancer
16 Mar 2026 //
GLOBENEWSWIRE
Cytomx Therapeutics Unveils 2026 Business Update And Milestones
08 Jan 2026 //
GLOBENEWSWIRE
Cytomx Therapeutics To Present At Jefferies London Health Conf
13 Nov 2025 //
GLOBENEWSWIRE
Cytomx Therapeutics Reveals Q3 2025 Financials & Business
06 Nov 2025 //
GLOBENEWSWIRE
Cytomx To Unveil CX-801 Phase 1 Biomarker Data At SITC Meeting
04 Nov 2025 //
GLOBENEWSWIRE
Cytomx Therapeutics Names Rachael Lester Chief Business Officer
20 Oct 2025 //
GLOBENEWSWIRE
CytomX to Present at September Investor Conferences
28 Aug 2025 //
GLOBENEWSWIRE
CytomX Reports Patient Death in Phase I Colorectal Cancer Study
15 Aug 2025 //
BIOSPACE
Cytom X Therapeutics Reveals Q2 2025 Financials and Updates
07 Aug 2025 //
GLOBENEWSWIRE
CytomX Therapeutics Set to Report Q2 2025 Financial Results
31 Jul 2025 //
GLOBENEWSWIRE
CytomX Therapeutics at Jefferies Global Healthcare Conference
29 May 2025 //
GLOBENEWSWIRE
CytomX Therapeutics: First Patient Dosed in CX-801 & Keytruda
19 May 2025 //
GLOBENEWSWIRE
CytomX Shares Interim Ph1 Data on CRC Drug CX-2051
12 May 2025 //
GLOBENEWSWIRE
CytomX Therapeutics Announces Q1 2025 Results and Update
12 May 2025 //
GLOBENEWSWIRE
CytomX Therapeutics Prices $100M Offering of Common Stock
12 May 2025 //
GLOBENEWSWIRE
CytomX Therapeutics to Report Q1 2025 Financial Results on May 12
05 May 2025 //
GLOBENEWSWIRE
CytomX presents preclinical data for mRNA Masked IL-12 at AACR
28 Apr 2025 //
GLOBENEWSWIRE
CytomX Therapeutics Announces 2024 Financial Results and Business
06 Mar 2025 //
GLOBENEWSWIRE
CytomX To Present At Barclays 27th Annual Healthcare Conference
05 Mar 2025 //
GLOBENEWSWIRE
CytomX Therapeutics to Report Q4 and Full Year 2024 Results
27 Feb 2025 //
GLOBENEWSWIRE
CytomX Outlines 2025 Pipeline Priorities And Updates
06 Jan 2025 //
GLOBENEWSWIRE
CytomX to Present at 36th Annual Piper Sandler Health Conference
27 Nov 2024 //
GLOBENEWSWIRE
CytomX Therapeutics Reports Q3 2024 Financial Results & Update
07 Nov 2024 //
GLOBENEWSWIRE
CytomX Therapeutics to Report Q3 2024 Results on Nov 7, 2024
31 Oct 2024 //
GLOBENEWSWIRE
CytomX Announces First Patient Dosed With CX-801
09 Sep 2024 //
GLOBENEWSWIRE
CytomX Therapeutics to Present at Upcoming Investor Conferences
04 Sep 2024 //
GLOBENEWSWIRE
CytomX To Report Q2 2024 Results On August 8
01 Aug 2024 //
GLOBENEWSWIRE
CytomX Therapeutics Announces New Employment Inducement Grants
16 May 2024 //
GLOBENEWSWIRE
CytomX Positive Phase 1a Data For CX-904 PROBODY Candidate
08 May 2024 //
GLOBENEWSWIRE
CytomX Collaboration to Evaluate CX-801 + KEYTRUDA®
07 May 2024 //
GLOBENEWSWIRE
CytomX Q1 2024 Results, CX-904 Phase 1a Data Update On May 8
01 May 2024 //
GLOBENEWSWIRE
CytomX Announces First Dosed with CX-2051 in a Ph 1 Study for Neoplasms
08 Apr 2024 //
GLOBENEWSWIRE
CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors
21 Mar 2024 //
GLOBENEWSWIRE
CytomX Therapeutics to Present at Upcoming March Investor Conferences
27 Feb 2024 //
GLOBENEWSWIRE
CytomX Therapeutics Outlines 2024 Company Priorities and Milestones
04 Jan 2024 //
GLOBENEWSWIRE
CytomX to Present at the 42nd Annual J.P. Morgan Healthcare Conference
21 Dec 2023 //
GLOBENEWSWIRE
Xencor pulls back from Genentech cancer pact to cut costs
08 Nov 2023 //
FIERCE BIOTECH
CytomX Therapeutics Reports Third Quarter 2023 Financial Results
07 Nov 2023 //
GLOBENEWSWIRE
CytomX Therapeutics to Present at Upcoming November Investor Conferences
01 Nov 2023 //
GLOBENEWSWIRE
CytomX to Present Data for Conditionally Activated Interferon Alpha-2b
30 Oct 2023 //
GLOBENEWSWIRE
CytomX Presents Profile of EpCAM-directed Antibody Drug Conjugate CX-2051
18 Oct 2023 //
GLOBENEWSWIRE
CytomX Therapeutics to Present at Upcoming September Investor Conferences
05 Sep 2023 //
GLOBENEWSWIRE
CytomX to Present at H.C. Wainwright Immune Cell Engager Virtual Conference
10 Aug 2023 //
GLOBENEWSWIRE
CytomX Therapeutics Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
GLOBENEWSWIRE
CytomX to Report Second Quarter 2023 Financial Results on August 8, 2023
01 Aug 2023 //
GLOBENEWSWIRE
CytomX Therapeutics Appoints Yu-Waye (Wayne) Chu, M.D., as Chief Medical Officer
17 Jul 2023 //
GLOBENEWSWIRE
CytomX Therapeutics to Present at the Jefferies Healthcare Conference
01 Jun 2023 //
GLOBENEWSWIRE
CytomX Therapeutics to Report First Quarter 2023 Financial Results on May 9,2023
01 May 2023 //
GLOBENEWSWIRE
Moderna teams up with CytomX in mRNA pact potentially worth over $1.2 billion
06 Jan 2023 //
GLOBENEWSWIRE
CytomX Therapeutics Provides Business Update and Outlines 2023 Company
05 Jan 2023 //
GLOBENEWSWIRE
